Boston's SQZ signs cancer drug pact with Roche worth up to $1B

Pharmaceutical giant Roche is re-upping its partnership with Boston startup SQZ Biotech, signing a collaboration deal on its lead cancer program that could be worth upwards of $1 billion. SQZ — pronounced "squeeze" — has developed a small chip that it hopes can allow proteins to penetrate a cell membrane, allowing the cells to be engineered in ways that other companies have struggled to do, according to founder and CEO Armon Sharei. The private biotech first signed a partners hip deal with…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news